Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Jul;40(7):1633–1639. doi: 10.1128/aac.40.7.1633

Prevalence of resistance to three fluoroquinolones: assessment of levofloxacin disk test error rates and surrogate predictors of levofloxacin susceptibility. AST Surveillance Group.

P C Fuchs 1, A L Barry 1, S D Brown 1
PMCID: PMC163386  PMID: 8807053

Abstract

More than 3,000 consecutive clinical bacterial isolates from 10 U.S. medical centers were subjected to standard broth microdilution and disk diffusion tests to determine their susceptibilities to levofloxacin, ofloxacin, D-ofloxacin, and ciprofloxacin. Levofloxacin was confirmed to be twice as active as ofloxacin and to have activity comparable to that of ciprofloxacin, with minor variations in activity against some species. The prevalence of resistant isolates was 7.1% to levofloxacin, 9.3% to ciprofloxacin, and 11.2% to ofloxacin. The susceptibilities of some species to the quinolones were less than those reported in previous studies. Pseudomonas aeruginosa isolates had the greatest variability in their susceptibilities to the three drugs between the participating centers. Two proposed zone size breakpoints for levofloxacin disk tests yielded similar low error rates. Ofloxacin and ciprofloxacin susceptibility test results correlated reasonably well with those of levofloxacin and could be used as surrogate indicators of levofloxacin susceptibility, but that resulted in some serious errors, and thus, direct testing of levofloxacin susceptibility is preferable. Replicate testing of standard quality control strains confirmed the established and proposed quality control parameters for all three quinolones tested.

Full Text

The Full Text of this article is available as a PDF (250.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bale M. J., Jones R. N., Erwin M. E. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group. Diagn Microbiol Infect Dis. 1994 May;19(1):65–68. doi: 10.1016/0732-8893(94)90054-x. [DOI] [PubMed] [Google Scholar]
  2. Barry A., Fuchs P., Tenover F., Allen S., Hardy D., Jorgensen J., McLaughlin J., Reller L. Interpretive criteria and quality control for antimicrobial susceptibility tests of levofloxacin. Eur J Clin Microbiol Infect Dis. 1994 Oct;13(10):822–826. doi: 10.1007/BF02111343. [DOI] [PubMed] [Google Scholar]
  3. Cherubin C. E., Eng R. H., Smith S. M., Tan E. N. A comparison of antimicrobial activity of ofloxacin, L-ofloxacin, and other oral agents for respiratory pathogens. Diagn Microbiol Infect Dis. 1992 Feb;15(2):141–144. doi: 10.1016/0732-8893(92)90038-u. [DOI] [PubMed] [Google Scholar]
  4. Cormican M. G., Jones R. N. Susceptibility to levofloxacin predicted from in vitro susceptibility testing results obtained with ciprofloxacin and with ofloxacin. J Clin Microbiol. 1995 Jan;33(1):215–216. doi: 10.1128/jcm.33.1.215-216.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Daum T. E., Schaberg D. R., Terpenning M. S., Sottile W. S., Kauffman C. A. Increasing resistance of Staphylococcus aureus to ciprofloxacin. Antimicrob Agents Chemother. 1990 Sep;34(9):1862–1863. doi: 10.1128/aac.34.9.1862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Dholakia N., Rolston K. V., Ho D. H., LeBlanc B., Bodey G. P. Susceptibilities of bacterial isolates from patients with cancer to levofloxacin and other quinolones. Antimicrob Agents Chemother. 1994 Apr;38(4):848–852. doi: 10.1128/aac.38.4.848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Foleno B. D., Lafredo S. C., Fu K. P. In vitro activity of levofloxacin, ofloxacin and other quinolones against coagulase-negative staphylococci. Chemotherapy. 1993 Mar-Apr;39(2):120–123. doi: 10.1159/000239112. [DOI] [PubMed] [Google Scholar]
  8. Foleno B., Fu K. P. In vitro activity of l-ofloxacin against norfloxacin-resistant coagulase-negative staphylococci. Diagn Microbiol Infect Dis. 1992 Aug;15(6):557–559. doi: 10.1016/0732-8893(92)90109-7. [DOI] [PubMed] [Google Scholar]
  9. Fu K. P., Lafredo S. C., Foleno B., Isaacson D. M., Barrett J. F., Tobia A. J., Rosenthale M. E. In vitro and in vivo antibacterial activities of levofloxacin (l-ofloxacin), an optically active ofloxacin. Antimicrob Agents Chemother. 1992 Apr;36(4):860–866. doi: 10.1128/aac.36.4.860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fuchs P. C., Jones R. N., Barry A. L., Gavan T. L. Ofloxacin susceptibility testing quality control parameters for microdilution and disk diffusion, and confirmation of disk diffusion interpretive criteria. J Clin Microbiol. 1989 Jan;27(1):49–52. doi: 10.1128/jcm.27.1.49-52.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fujimoto T., Mitsuhashi S. In vitro antibacterial activity of DR-3355, the S-(-)-isomer of ofloxacin. Chemotherapy. 1990;36(4):268–276. doi: 10.1159/000238777. [DOI] [PubMed] [Google Scholar]
  12. Goodwin S. D., Gallis H. A., Chow A. T., Wong F. A., Flor S. C., Bartlett J. A. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1994 Apr;38(4):799–804. doi: 10.1128/aac.38.4.799. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hayakawa I., Atarashi S., Yokohama S., Imamura M., Sakano K., Furukawa M. Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother. 1986 Jan;29(1):163–164. doi: 10.1128/aac.29.1.163. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Houston A. K., Jones R. N. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. Diagn Microbiol Infect Dis. 1994 Jan;18(1):57–59. doi: 10.1016/0732-8893(94)90134-1. [DOI] [PubMed] [Google Scholar]
  15. Imamura M., Shibamura S., Hayakawa I., Osada Y. Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother. 1987 Feb;31(2):325–327. doi: 10.1128/aac.31.2.325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Klesel N., Geweniger K. H., Koletzki P., Isert D., Limbert M., Markus A., Riess G., Schramm H., Iyer P. Chemotherapeutic activity of levofloxacin (HR 355, DR-3355) against systemic and localized infections in laboratory animals. J Antimicrob Chemother. 1995 Jun;35(6):805–819. doi: 10.1093/jac/35.6.805. [DOI] [PubMed] [Google Scholar]
  17. Metzler C. M., DeHaan R. M. Susceptibility tests of anaerobic bacteria: statistical and clinical considerations. J Infect Dis. 1974 Dec;130(6):588–594. doi: 10.1093/infdis/130.6.588. [DOI] [PubMed] [Google Scholar]
  18. Morissey I., Smith J. T. Activity of 4-quinolones against Pseudomonas aeruginosa. Arzneimittelforschung. 1994 Oct;44(10):1157–1161. [PubMed] [Google Scholar]
  19. Neu H. C., Chin N. X. In vitro activity of S-ofloxacin. Antimicrob Agents Chemother. 1989 Jul;33(7):1105–1107. doi: 10.1128/aac.33.7.1105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pfaller M. A., Barry A. L., Fuchs P. C. Levofloxacin disk potency and tentative interpretive criteria for susceptibility tests. J Clin Microbiol. 1993 Jul;31(7):1924–1926. doi: 10.1128/jcm.31.7.1924-1926.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shalit I., Berger S. A., Gorea A., Frimerman H. Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital. Antimicrob Agents Chemother. 1989 Apr;33(4):593–594. doi: 10.1128/aac.33.4.593. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Sutton L. D., Jones R. N. Suggested modifications for disk diffusion susceptibility testing criteria for levofloxacin and sparfloxacin following tests with a predictor panel of ciprofloxacin-resistant clinical isolates. J Clin Microbiol. 1995 Jan;33(1):146–148. doi: 10.1128/jcm.33.1.146-148.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Une T., Fujimoto T., Sato K., Osada Y. In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother. 1988 Sep;32(9):1336–1340. doi: 10.1128/aac.32.9.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Venezio F. R., Tatarowicz W., DiVincenzo C. A., O'Keefe J. P. Activity of ciprofloxacin against multiply resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, and group JK corynebacteria. Antimicrob Agents Chemother. 1986 Dec;30(6):940–941. doi: 10.1128/aac.30.6.940. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Yamane N., Jones R. N., Frei R., Hoban D. J., Pignatari A. C., Marco F. Levofloxacin in vitro activity: results from an international comparative study with ofloxacin and ciprofloxacin. J Chemother. 1994 Apr;6(2):83–91. doi: 10.1080/1120009x.1994.11741134. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES